We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Genomic Prostate Score Test Evaluated as Prognosis Predictor

By LabMedica International staff writers
Posted on 13 Jul 2020
Molecular assays, including multi-gene expression assays, are increasingly used clinically to improve risk stratification for men with newly diagnosed prostate cancer (PCa). More...


The problem for men with unfavorable intermediate (UFI)-risk PCa is that until now, the lack of definitive knowledge about this particular subtype has made it almost impossible to opt for active surveillance, despite the fact that some of them end up with less aggressive disease.

Cancer specialist at the Case Western Reserve University (Cleveland, OH, USA) and their colleagues analyzed the associations multi-gene expression assay with results with biochemical recurrence (BCR), distant metastases (DM) and prostate-specific death (PCD) in two cohorts of men with UFI prostate cancer who were treated with radical prostatectomy. The analyses included 299 intermediate-risk prostate patients, 175 of whom had UFI-risk disease; 103 from the Kaiser Permanente Northern California (KPNC) cohort and 72 from the Center for Prostate Disease Research (CDPR) cohort.

The assay used in the study was the Oncotype DX Genomic Prostate Score (GPS), (Genomic Health, Inc, Redwood City, CA, USA). The test is a quantitative reverse transcriptase polymerase chain reaction assay that measures the expression levels of 17 genes (12 cancer-related and five reference) in messenger RNA extracted from microdissected tumor tissue obtained from fixed prostate needle biopsies. It provides a GPS result scaled from 0 to 100 as a molecular measure of increasing tumor aggressiveness. It has been analytically and clinically validated as a significant independent predictor of multiple endpoints in men with newly diagnosed low and intermediate risk PCa.

The scientists reported that the GPS result as a dichotomous value (≤40 versus >40) was a significant predictor of BCR in UFI patients in multivariate analyses (hazard ratio [HR] 6.0; 95% confidence interval [CI] 2.0-22.4). The GPS result was a strong predictor of all three endpoints in multivariate analyses: BCR = HR 7.1; DM HR= 5.4; PCD HR =3.4. UFI patients with GPS >40 had outcomes consistent with high-risk disease, whereas UFI patients with GPS ≤40 had outcomes similar to FI risk patients (CPDR/KPNC).

Jennifer Cullen, PhD, MPH, an Associate Professor and the lead author of the study, said, “No one had focused specifically on unfavorable intermediate. And that's important because there is a gray zone, a very murky area, in knowing how aggressively to treat that disease, because we don't know if it's going to behave more like high-risk disease or more like favorable intermediate-risk disease. You are always trying to strike a careful balance between preserving oncologic outcome and sparing patients decrements in quality of life. So, there's this very careful discussion and balance that patients and doctors have to strike in deciding what treatment course to pursue for men in that gray zone.”

The authors concluded that the GPS result was a strong independent predictor of BCR, DM, and PCD in intermediate risk prostate cancer. UFI patients with GPS >40 have a poor prognosis and may benefit from additional therapeutic options. The study was published on June 7, 2020 in the journal Urology.

Related Links:
Case Western Reserve University
Genomic Health



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gel Cards
DG Gel Cards
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
Image: (A) Normal skin and (B) possible pathology in ALS skin (Photo courtesy of Biomolecules and Biomedicine (2025) DOI: 10.17305/bb.2025.12100)

Skin-Based Biomarkers to Enable Early Diagnosis of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that damages motor neurons in the brain and spinal cord, causing muscle weakness, paralysis, and death within three to five... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.